1-9 of 9
Eric Angevin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters, Eric Angevin, Teresa Alonso-Gordoa, Kristoffer Rohrberg, Ignacio Melero, Begoña Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christian Klein, Barbara Leutgeb, Pavel Pisa, Eva Rossmann, José Saro, Pablo Umana, Jehad Charo, Volker Teichgräber, Neeltje Steeghs
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1630–1641.
https://doi.org/10.1158/1078-0432.CCR-23-2658
Published: 15 April 2024
View article titled, Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Open the PDF for Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip B. Komarnitsky, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5781–5792.
https://doi.org/10.1158/1078-0432.CCR-21-0765
Published: 01 November 2021
View article titled, Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Open the PDF for Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma in another window
Includes: Supplementary data
Journal Articles

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo-Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Lambros Tselikas, Eric Solary, Eric Angevin, Alexander M. Eggermont, Fabrice Andre, Christophe Massard, Ken A. Olaussen, Jean-Charles Soria, Benjamin Besse, Luc Friboulet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 242–255.
https://doi.org/10.1158/1078-0432.CCR-19-1104
Published: 03 January 2020
View article titled, Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Open the PDF for Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andrea Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean-Marie Michot, Sophie Postel-Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean-Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 946–956.
https://doi.org/10.1158/1078-0432.CCR-18-0793
Published: 01 February 2019
View article titled, Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Open the PDF for Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation in another window
Includes: Supplementary data
Journal Articles

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen-Chuan Ou, Daniel Castellano, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Sarah Beall, Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 3012–3022.
https://doi.org/10.1158/1078-0432.CCR-13-3006
Published: 29 May 2014
View article titled, Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Open the PDF for Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Eric Angevin, Josep Tabernero, Elena Elez, Steven J. Cohen, Rastilav Bahleda, Jean-Luc van Laethem, Christian Ottensmeier, Jose A. Lopez-Martin, Sally Clive, Florence Joly, Isabelle Ray-Coquard, Luc Dirix, Jean-Pascal Machiels, Neil Steven, Manjula Reddy, Brett Hall, Thomas A. Puchalski, Rajesh Bandekar, Helgi van de Velde, Brenda Tromp, Jessica Vermeulen, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2192–2204.
https://doi.org/10.1158/1078-0432.CCR-13-2200
Published: 15 April 2014
View article titled, A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Eric Angevin, Jose A. Lopez-Martin, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean-Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1257–1268.
https://doi.org/10.1158/1078-0432.CCR-12-2885
Published: 03 March 2013
View article titled, Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Open the PDF for Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma

Bruce Elliott, Richard A. Scolyer, Stefan Suciu, Serge Lebecque, Donata Rimoldi, Oliver Gugerli, Elena Musat, Raghwa N. Sharma, Danielle Lienard, Ulrich Keilholz, Alessandro Testori, Alexander Eggermont, Rona MacKie, Caroline Robert, Martin Cook, John F. Thompson, Eric Angevin, Alain Spatz, on behalf of the European Organization for Research and Treatment of Cancer Melanoma Group
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3825–3830.
https://doi.org/10.1158/1078-0432.CCR-07-0358
Published: 02 July 2007
View article titled, Long-Term Protective Effect of Mature DC-LAMP<sup>+</sup> Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma
Open the PDF for Long-Term Protective Effect of Mature DC-LAMP<sup>+</sup> Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma in another window
Journal Articles

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

Bernard Escudier, Nathalie Lassau, Eric Angevin, Jean Charles Soria, Linda Chami, Michele Lamuraglia, Eric Zafarana, Veronique Landreau, Brian Schwartz, Eric Brendel, Jean-Pierre Armand, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1801–1809.
https://doi.org/10.1158/1078-0432.CCR-06-1432
Published: 15 March 2007
View article titled, Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
Open the PDF for Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma in another window